Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07729072
Starting soon Not applicable

The Effect of Olive Leaf Extract Supplementation on Training-induced Skeletal Muscle Functional and Molecular Adaptations in Healthy Volunteers

NCT07729072 · tracked via the Priya Life Science Switzerland tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-07-27

Condition(s) studied

Healthy Adult ParticipantsExercise TrainingNeuromuscular AdaptationsNutritional Intervention

Investigational drug(s) / intervention(s)

Olive leaf extractPlacebo

Olive leaf extract: A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water daily for 21 days.

Placebo: A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water daily for 21 days.

Study summary

The goal of this study is to investigate the effect of combining olive leaf extract supplementation with endurance training (moderate intensity continuous training or sprint interval training). We hypothesize that OLE supplementation during training, as compared to training alone with placebo, will translate into better performance outcomes. More specifically, we hypothesize that the additional benefits of OLE supplementation on performance will be mediated by improved mitochondrial characteristics in skeletal muscle and increased neural activation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Being between 18 and 45 years old 2. Being healthy (assessed through the PAR-Q questionnaire). 3. Being physically active, but not involved in any structured training program 4. Being available for the study period. Exclusion Criteria: 1. If a participant answers positively to any YES/NO question in the PAR-Q health questionnaire. For questions requiring a precision, any positive answer will be reviewed by a medical doctor, who will determine the inclusion/exclusion of the participant. 2. Having allergy to xylocaine 3. Being pregnant.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bâtiment Synathlon, quartier UNIL-Centre Lausanne Switzerland

More University of Lausanne trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07729072 on ClinicalTrials.gov ↗ ← All trials in Switzerland